Filing Flows › Quest Diagnostics (DGX) › Guidance & outlook

Quest Diagnostics (DGX) guidance and outlook

Quest Diagnostics (DGX) raised its guidance on Oct 22, 2026: Revenue $12.1B for FY2026; EPS $10.21–$10.31 for FY2026; EPS $11.25–$11.35 for FY2026; Revenue +9.7% for FY2026.

Guidance and outlook

Met or beat 2 of 2 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	FY2026	$12.1B	raised
EPS	FY2026	$10.21–$10.31	raised
EPS	FY2026	$11.25–$11.35	raised
Revenue	FY2026	+9.7%	raised
Capital expenditures	FY2026	$550M	reaffirmed

From the earnings release filed Oct 22, 2026 (8-K on EDGAR).

Quest Diagnostics' latest quarter

Quest Diagnostics, Q3 2026: revenue $3.1B (+10% year over year), operating margin 15.5%, net earnings $312M, operating cash flow $611M. The chart follows the revenue to costs, profit and cash.

Questions

Did Quest Diagnostics raise or lower its guidance?

Quest Diagnostics (DGX) raised its guidance on Oct 22, 2026: Revenue $12.1B for FY2026; EPS $10.21–$10.31 for FY2026; EPS $11.25–$11.35 for FY2026; Revenue +9.7% for FY2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.